|
Regimen
|
All patients (N = 147)
|
Patients who were evaluated for SVR (N = 132)
|
Patients with treatment discontinuation or loss to follow-up (N = 15)
|
Virologic responses
|
|---|
|
RVR (N = 109)
|
SVR (N = 132)
|
|---|
|
Rate (%)
|
95% CI of %*
|
Rate (%)
|
95% CI of %*
|
|---|
|
SOF/LDV 12 W
|
32 (21.8%)
|
30 (22.7%)
|
2 (13.3%)
|
15/16 (93.8%)
|
69.8–99.8%
|
30/30 (100%)
|
88.4–100%
|
|
SOF/LDV 24 W
|
9 (6.1%)
|
7 (5.3%)
|
2 (13.3%)
|
9/9 (100%)
|
66.4–100%
|
7/7 (100%)
|
59.0–100%
|
|
SOF/LDV + RBV 12 W
|
46 (31.3%)
|
42 (31.8%)
|
4 (26.6%)
|
39/41 (95.1%)
|
83.5–99.4%
|
42/42 (100%)
|
91.6–100%
|
|
SOF/LDV + RBV 24 W
|
7 (4.8%)
|
6 (4.5%)
|
1 (6.7%)
|
3/6 (50%)
|
11.8–88.2%
|
6/6 (100%)
|
54.1–100%
|
|
SOF/DCV 12 W
|
22 (15%)
|
20 (15.1%)
|
2 (13.3%)
|
14/14 (100%)
|
76.9–100%
|
20/20 (100%)
|
83.2–100%
|
|
SOF/DCV 24 W
|
4 (2.7%)
|
3 (2.3%)
|
1 (6.7%)
|
2/2 (100%)
|
15.8–100%
|
3/3 (100%)
|
29.2–100%
|
|
SOF/DCV + RBV 12 W
|
5 (3.4%)
|
4 (3.1%)
|
1 (6.7%)
|
3/3 (100%)
|
29.2–100%
|
4/4 (100%)
|
39.8–100%
|
|
SOF/DCV + RBV 24 W
|
13 (8.8%)
|
12 (9.1%)
|
1 (6.7%)
|
13/13 (100%)
|
75.3–100%
|
12/12 (100%)
|
73.5–100%
|
|
SOF/VEL 12 W
|
7 (4.7%)
|
7 (5.3%)
|
0 (0%)
|
4/4 (100%)
|
39.8–100%
|
7/7 (100%)
|
59.0–100%
|
|
SOF/VEL 24 W
|
1 (0.7%)
|
0 (0%)
|
1 (6.7%)
|
NA
|
NA
|
NA
|
NA
|
|
SOF + RBV 24 W
|
1 (0.7%)
|
1 (0.8%)
|
0 (0%)
|
1/1 (100%)
|
2.5–100%
|
1/1 (100%)
|
2.5–100%
|
|
Total
|
147 (100%)
|
132 (100%)
|
15 (100%)
|
103/109 (94.5%)
|
88.4–98.0%
|
132/132 (100%)
|
97.2–100%
|
- SOF sofosbuvir, LDV ledipasvir, DCV daclatasvir, VEL velpatasvir, RBV ribavirin, W weeks, RVR rapid virologic response, SVR sustained virologic response, NA not available, CI confidence interval, N number
- *Binomial exact calculation
